publication date: Jan. 19, 2018
Issue 3 - Jan. 19, 2018
  • Guest Editorial

    A unique drug for each patient: a paradigm shift in cancer therapy

    The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

  • News Analysis

    As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration

    As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.

  • In Brief

    • Allison, Bax, Doudna and Chang receive NAS prizes
    • Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago
    • ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements
    • ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth
  • TCCL Logo

  • Clinical Roundup

    • Blood test for eight cancer types provides framework for early detection
    • Study shows screening population for select genes is a cost-effective solution
    • Polygenic hazard score predicts when men develop prostate cancer
    • Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma
  • Drugs and Targets

    • Foundation Medicine and Pfizer form partnership to develop companion diagnostics
    • FDA approves addition of overall survival data to Kyprolis
    • Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL
  • CTEP Protocols

    NCI CTEP-Approved Trials for January

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.

Copyright (c) 2018 The Cancer Letter Inc.